|             Group | Type | Cat. No. | Product | Activity | 
 
  | β-catenin  Peptides |  | 6531 | NLS-StAx-h | Wnt
  signaling inhibitor; inhibits β-catenin-transcription factor interactions | 
 
  | 7298 | xStAx-VHLL | Selective
  peptide-based β-catenin Degrader | 
 
  | δ Opioid Receptor  Peptides | Agonists | 3790 | DADLE | Prototypical
  δ agonist | 
 
  | 1180 | [D-Ala2]-Deltorphin
  II | Selective
  δ agonist peptide | 
 
  | 1431 | DPDPE | Selective
  δ agonist | 
 
  | Antagonists | 0820 | ICI
  174,864 | δ
  selective peptide antagonist | 
 
  | κ Opioid Receptor  Peptides | Agonists | 3195 | Dynorphin
  A | Endogenous
  κ agonist | 
 
  | 7541 | Helianorphin-19 | Potent
  and selective G protein-biased κ opioid receptor (KOR) agonist | 
 
  | μ Opioid Receptor  Peptides | Agonists | 1171 | DAMGO | Selective
  μ agonist | 
 
  | 1055 | Endomorphin-1 | Potent
  and selective μ agonist | 
 
  | Antagonists | 1560 | CTAP | Potent
  and selective μ antagonist | 
 
  | 1578 | CTOP | Potent
  and selective μ antagonist | 
 
  | 14.3.3 Protein  Peptides | Inhibitors | 2144 | R18 | Inhibitor
  of 14.3.3 proteins | 
 
  | A-Kinase-Anchoring  Proteins Peptides | Inhibitors | 6286 | st-Ht31 | Inhibits
  PKA/AKAP interactions; cell permeable | 
 
  | ACE2 Peptides | Inhibitors | 5213 | LL
  37 | Inhibitor
  of SARS-CoV-2 S1 spike protein and ACE2 interaction | 
 
  | Substrates | 1563 | Angiotensin
  I (human, mouse, rat) | Potent
  endogenous vasoconstrictor peptide; substrate for ACE and ACE2 | 
 
  | 1158 | Angiotensin
  II | Potent
  endogenous vasoconstrictor peptide; substrate for ACE2 | 
 
  | Other | 7233 | SBP1 | ACE2
  derived peptide; binds SARS-CoV-2 spike protein receptor binding domain | 
 
  | 7322 | SP
  10 | Highly
  potent inhibitor of SARS-CoV Spike (S) protein and ACE2 interaction | 
 
  | Acid-Sensing  Ion Channel Peptides | Blockers | 4804 | APETx2 | ASIC3
  channel blocker | 
 
  | 5042 | Psalmotoxin
  1 | Potent
  and selective ASIC1a channel blocker | 
 
  | Actin Peptides |  | 4535 | Phalloidin | Promotes
  actin polymerization | 
 
  | Active Degrader  Peptides | Degraders | 7388 | ND1-YL2 | SRC-1
  peptide-based PROTAC®; active in vivo | 
 
  | 7298 | xStAx-VHLL | Selective
  peptide-based β-catenin Degrader (PROTAC®) | 
 
  | ADAM Peptides | Inhibitors | 5523 | TAPI
  0 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | 6162 | TAPI
  1 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | 6013 | TAPI
  2 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | Adenylyl Cyclase  Peptides | Activators | 1183 | PACAP
  1-27 | Potently
  stimulates adenylyl cyclase | 
 
  | 1186 | PACAP
  1-38 | Potently
  stimulates adenylyl cyclase | 
 
  | Amyloid β Peptide  Peptides | Inhibitors | 6779 | Davunetide | Highly
  potent active component of ADNP; prevents amyloid β aggregation;
  active in vivo | 
 
  | Other | 1191 | Amyloid
  β-Peptide (1-40) (human) | Amyloid
  β-protein fragment | 
 
  | 1428 | Amyloid
  β-Peptide (1-42) (human) | Predominant
  amyloid β-protein fragment | 
 
  | 2425 | Amyloid
  β-peptide (1-42) (rat) | Predominant
  amyloid β-protein fragment | 
 
  | 1429 | Amyloid
  β-peptide (25-35) (human) | Human
  amyloid β-protein fragment functionally required for neurotoxicity | 
 
  | 3945 | Colivelin | Neuroprotective
  peptide; protects against β-amyloid neurotoxicity | 
 
  | 6517 | Liraglutide | Reduces
  Aβ and soluble amyloid levels in vivo; also highly potent GLP-1 receptor
  agonist | 
 
  | 7712 | Semax | Reduces
  Aβ aggregation and fibrillogenesis; neuroprotective and neurotrophic peptide | 
 
  | Angiotensin AT2  Receptor Peptides | Ligands | 2569 | CGP
  42112 | Selective,
  high affinity AT2 ligand | 
 
  | Angiotensin- Converting Enzyme  Peptides | Substrates | 1563 | Angiotensin
  I (human, mouse, rat) | Endogenous
  peptide substrate of ACE and ACE2 | 
 
  | 3791 | Hemopressin
  (human, mouse) | Bioactive
  substrate for endopeptidase 24.15, neurolysin and ACE | 
 
  | Antiangiogenic  Peptides | Inhibitors | 4664 | Obtustatin | Potent
  and selective α1β1 inhibitor; antiangiogenic | 
 
  | AP-1 Peptides | Inhibitors | 1989 | c-JUN
  peptide | JNK/c-Jun
  interaction inhibitor | 
 
  | Apelin Receptor  Peptides | Agonists | 2420 | [Pyr1]-Apelin-13 | Potent
  peptide apelin agonist | 
 
  | 3007 | Apelin-17
  (human, bovine) | Endogenous
  apelin agonist | 
 
  | 2426 | Apelin-36
  (human) | Endogenous
  apelin agonist | 
 
  | Antagonists | 5992 | MM
  54 | Potent
  apelin antagonist | 
 
  | Autophagy Peptides | Inhibitors | 1190 | Pepstatin
  A | Protease
  inhibitor; interferes with autolysosomal digestion | 
 
  | Biochemicals and  Molecular Biology  Peptides |  | 7723 | RGD
  peptide | Directs
  association of cells with diverse biomaterials and surfaces | 
 
  | Blocking Buffer and  Reagent Peptides |  | 5217 | Bovine
  Serum Albumin | Blocking
  reagent used in blocking buffer for use in ICC and IHC | 
 
  | Bombesin Receptor  Peptides | Agonists | 1789 | GRP
  (human) | Endogenous
  GRP receptor agonist | 
 
  | Other | 1908 | Neuromedin
  B (porcine) | Mammalian
  bombesin-like peptide | 
 
  | Bradykinin Receptor  Peptides | Agonists | 3004 | Bradykinin | Endogenous
  agonist at bradykinin receptors (B2 > B1) | 
 
  | 3229 | [Phe8Ψ(CH-NH)-Arg9]-Bradykinin | Selective
  B2 agonist | 
 
  | 3225 | Lys-[Des-Arg9]Bradykinin | Selective
  B1 agonist | 
 
  | Antagonists | 3014 | HOE
  140 | Potent
  and selective B2 antagonist | 
 
  | 3407 | R
  715 | Potent
  and selective B1 antagonist | 
 
  | Buffers, Solvents and  Solution Peptides |  | 5217 | Bovine
  Serum Albumin | BSA
  (bovine serum albumin) is a blocking buffer for IHC, ICC, ELISA and Western
  blotting; used to block non-specific antibody binding. Commonly used in cell
  culture | 
 
  | CaV2.x Channel  Peptides | Blockers | 2799 | ω-Agatoxin
  IVA | CaV2.1
  blocker | 
 
  | 2802 | ω-Agatoxin
  TK | CaV2.1
  blocker | 
 
  | 1085 | ω-Conotoxin
  GVIA | CaV2.2
  blocker | 
 
  | 2945 | SNX
  482 | Potent
  and selective CaV2.3 blocker | 
 
  | Calcitonin and  Related Receptor  Peptides | Agonists | 3418 | Amylin | Endogenous
  peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptors | 
 
  | 6031 | Calcitonin
  (human) | Endogenous
  calcitonin agonist; inhibits bone resorption | 
 
  | 1159 | Calcitonin
  (salmon) | Affects
  bone formation and resorption | 
 
  | 3012 | α-CGRP
  (human) | CGRP
  agonist | 
 
  | 1161 | CGRP
  (rat) | Potent
  vasodilator | 
 
  | 5031 | Pramlintide | Synthetic
  version of amylin (Cat. No. 3418) | 
 
  | Antagonists | 3419 | AC
  187 | Potent
  and selective amylin antagonist | 
 
  | 1181 | CGRP
  8-37 (human) | CGRP
  antagonist | 
 
  | 1169 | CGRP
  8-37 (rat) | CGRP
  antagonist | 
 
  | Calcium Binding  Protein  Peptides | Agonists | 2090 | CALP1 | Cell-permeable
  calmodulin agonist | 
 
  | Inhibitors | 1688 | Autocamtide-2-related
  inhibitory peptide | Selective
  CaM kinase II inhibitor | 
 
  | 5959 | Autocamtide-2-related
  inhibitory peptide, myristoylated | CaM
  kinase II inhibitor; enhanced cell permeable derivative
  of Autocamtide-2-related inhibitory peptide | 
 
  | 1885 | MLCK
  inhibitor peptide 18 | Selective
  inhibitor of myosin light chain kinase | 
 
  | Calcium-Activated  Potassium (KCa)  Channel Peptides | Blockers | 1652 | Apamin | KCa2
  (SK) channel blocker | 
 
  | 1086 | Iberiotoxin | KCa (BK)
  channel blocker | 
 
  | Calcium-Sensitive  Protease Peptides | Inhibitors | 2950 | Acetyl-Calpastatin
  (184-210) (human) | Selective
  calpain inhibitor | 
 
  | Calmodulin- Dependent Kinase  Peptides | Inhibitors | 1688 | Autocamtide-2-related
  inhibitory peptide | Selective
  CaM kinase II inhibitor | 
 
  | 5959 | Autocamtide-2-related
  inhibitory peptide, myristoylated | CaM
  kinase II inhibitor; enhanced cell permeable derivative
  of Autocamtide-2-related inhibitory peptide | 
 
  | Calpain Peptides | Inhibitors | 2950 | Acetyl-Calpastatin
  (184-210) (human) | Selective
  calpain inhibito | 
 
  | Caspase Peptides | Inhibitors | 7242 | Ac-FLTD-CMK | Potent
  and selective inhibitor of caspases 1, 5 and 4 | 
 
  | 2166 | Z-DEVD-FMK | Cell-permeable,
  irreversible caspase-3 inhibitor | 
 
  | 8009 | Z-DEVD-FMK
  Caspase-3 Inhibitor New | Caspase-3
  Inhibitor | 
 
  | 2163 | Z-VAD-FMK | Cell-permeable,
  irreversible caspase inhibitor | 
 
  | Cathepsin Peptides | Inhibitors | 1190 | Pepstatin
  A | Selective
  and high affinity cathepsin D inhibitor | 
 
  | CB1 Receptor  Peptides | Inverse
  Agonists | 3791 | Hemopressin
  (human, mouse) | Selective
  CB1 inverse agonist | 
 
  | CCK1 Receptor  Peptides | Agonists | 2411 | A-71623 | Potent
  and selective CCK1 agonist; suppresses feeding | 
 
  | CCK2 Receptor  Peptides | Agonists | 3006 | Gastrin
  I (human) | Selective
  CCK2 agonist | 
 
  | Cell Adhesion  Molecule Peptides | Inhibitors | 7723 | RGD
  peptide | Minimal
  recognition sequence for integrin binding; potent integrin inhibitor | 
 
  | Other | 1845 | Ac2-26 | Annexin/lipocortin
  1-mimetic; inhibits leukocyte extravasation | 
 
  | 3910 | BIO
  1211 | Selective
  α4β1 (VLA-4) inhibitor | 
 
  | 5870 | Cilengitide | Potent
  and selective inhibitor of integrins αvβ3 and αvβ5 | 
 
  | 3202 | Echistatin,
  α1 isoform | Integrin
  αVβ3 and glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor | 
 
  | 4725 | Eptifibatide | Glycoprotein
  IIb/IIIa inhibitor; inhibits platelet aggregation | 
 
  | 4577 | LDV
  FITC | Fluorescent
  ligand for α4β1 (VLA-4) | 
 
  | 4664 | Obtustatin | Potent
  and selective α1β1 inhibitor | 
 
  | 3498 | RGDS
  peptide | Integrin
  binding sequence; inhibits integrin receptor function | 
 
  | Chemokine CC  Receptor Peptides | Antagonists | 2423 | DAPTA | Chemokine
  receptor 5 (CCR5) antagonist | 
 
  | Chemokine CXC  Receptor Peptides | Agonists | 5795 | ATI
  2341 | CXCR4
  allosteric agonist | 
 
  | Antagonists | 5130 | CTCE
  9908 | CXCR4
  antagonist; antitumor | 
 
  | 4300 | TC
  14012 | CXCR4
  antagonist; ACKR3 (CXCR7) agonist | 
 
  | Complement  Peptides | Antagonists | 5196 | PMX
  205 | Potent
  C5a receptor peptide antagonist | 
 
  | 5473 | PMX
  53 | Potent
  C5a receptor antagonist | 
 
  | Controls | 3796 | Compstatin
  control peptide | Control
  peptide for Compstatin (Cat. No. 2585) | 
 
  | 5697 | PMX
  53c | Negative
  control for PMX 53 (Cat. No. 5473) | 
 
  | Other | 2585 | Compstatin | C3-binding
  peptide; inhibits complement activation | 
 
  | Coronavirus Antiviral  Peptides |  | 5213 | LL
  37 | Inhibits
  interaction between SAR-CoV-2 S1 protein and ACE2; human cathelicidin peptide
  derivative | 
 
  | CRF1 Receptor  Peptides | Agonists | 1608 | Stressin
  I | CRF1 agonist | 
 
  | CRF2 Receptor  Peptides | Agonists | 2391 | Astressin
  2B | Selective
  CRF2 antagonist | 
 
  | 2070 | K
  41498 | Highly
  selective and potent CRF2 antagonist | 
 
  | Cytokine Receptor  Peptides | Antagonists | 1793 | AF
  12198 | Potent,
  selective human type I IL-1 receptor antagonis | 
 
  | Dynamin Peptides | Inhibitors | 1774 | Dynamin
  inhibitory peptide | Dynamin
  inhibitor | 
 
  | 1775 | Dynamin
  inhibitory peptide, myristoylated | Cell-permeable
  dynamin inhibitor | 
 
  | 6897 | P110 | Dynamin-related
  protein 1 (Drp1) inhibitor; cell-permeable | 
 
  | Enzyme Probes and  Enzyme Substrate  Peptides |  | 7287 | FAM-DEALA-Hyp-YIPD | Fluorescent
  HIF-1α peptide; can be used to evaluate the effect of VHL binding on
  degradation activity | 
 
  | 7452 | FAM-DEALAHypYIPMDDDFQLRSF | Fluorescent
  HIF-1α peptide | 
 
  | 7627 | FITC-labelled
  Keap1-Nrf2 probe | Fluorescent
  Keap1-Nrf2 peptide | 
 
  | Enzyme Substrate  / Activator Peptides | Substrates | 3791 | Hemopressin
  (human, mouse) | Bioactive
  substrate for endopeptidase 24.15, neurolysin and ACE | 
 
  | Activators | 1983 | 740
  Y-P | Cell-permeable
  PI 3-kinase activator | 
 
  | Eph Receptor  Peptides | Inhibitors | 5290 | KYL | EphA4
  kinase inhibitor; neuroprotective | 
 
  | ETA Receptor  Peptides | Antagonists | 1188 | BQ-123 | Selective
  ETA antagonist | 
 
  | ETB Receptor  Peptides | Agonists | 1189 | BQ-3020 | Selective
  ETB agonist | 
 
  | 1196 | IRL-1620 | Highly
  selective ETB agonist | 
 
  | 1175 | Sarafotoxin
  S6c | Selective
  ETB agonist | 
 
  | Fluorescent Integrin  Probe Peptides |  | 4577 | LDV
  FITC | Fluorescent
  ligand for α4β1 (VLA-4) | 
 
  | Fluorescent Receptor  Probe Peptides |  | 4577 | LDV
  FITC | Fluorescent
  ligand for α4β1 (VLA-4) | 
 
  | Formyl Peptide  Receptor Peptides | Agonists | 1921 | N-Formyl-Met-Leu-Phe | Endogenous
  FPR1 agonist | 
 
  | 3537 | MMK
  1 | Potent
  and selective FPR2 agonist | 
 
  | 1800 | WKYMVm | FPR1,
  FPR2 and FPR3 receptor agonist | 
 
  | Antagonists | 3730 | Boc-MLF | FPR1
  antagonist | 
 
  | 4611 | PBP
  10 | Selective
  FPR2 antagonist; cell permeable | 
 
  | 2262 | WRW4 | Selective
  FPR2 antagonist | 
 
  | Furin Peptides | Inhibitors | 3501 | Decanoyl-RVKR-CMK | Furin
  inhibitor; blocks SARS-CoV-2 spike protein cleavage and blocks viral cell
  entry | 
 
  | 4711 | Hexa-D-arginine | Furin
  inhibitor | 
 
  | Galanin Receptor  Peptides | Agonists | 2696 | Galanin
  (1-29) (rat, mouse) | Non-selective
  galanin receptor agonist | 
 
  | 1179 | Galanin
  (1-30) (human) | Endogenous
  galanin receptor agonist | 
 
  | 2697 | M617 | Selective
  GAL1 agonist | 
 
  | 6090 | Spexin | Potent
  GAL2/3 agonist; exhibits anxiolytic effects in vivo | 
 
  | Antagonists | 3425 | M40 | Potent,
  non-selective galanin receptor antagonist | 
 
  | 2698 | M871 | Selective
  GAL2 antagonist | 
 
  | Gap Channel Peptides | Blockers | 3348 | 10Panx | Panx-1
  mimetic inhibitory peptide; blocks pannexin-1 gap junctions | 
 
  | 1950 | Gap
  26 | Gap
  junction blocker; inhibits smooth muscle contraction and IP3-mediated ATP
  release | 
 
  | 1476 | Gap
  27 | Selective
  gap junction blocker | 
 
  | 5353 | Gap19 | Cx43
  hemichannel blocker | 
 
  | 6227 | TAT-Gap19 | Cx43
  hemichannel blocker | 
 
  | Controls | 7402 | TAT-Gap19(I130A) | Control
  peptide for TAT-Gap19 | 
 
  | Ghrelin Receptor  Peptides | Agonists | 1463 | Ghrelin
  (human) | Endogenous
  ghrelin receptor agonist | 
 
  | 1465 | Ghrelin
  (rat) | Endogenous
  ghrelin receptor agonist | 
 
  | Antagonists | 1922 | [D-Lys3]-GHRP-6 | Ghrelin
  receptor antagonist | 
 
  | Other | 3374 | Cortistatin
  14 | Endogenous
  neuropeptide; binds ghrelin receptor and sst1 - sst5 | 
 
  | 2951 | [Des-octanoyl]-Ghrelin
  (rat) | Major
  circulating form of ghrelin; devoid of activity at GHS receptor | 
 
  | GIP Receptor  Peptides | Agonists | 2257 | GIP
  (1-39) | Highly
  potent insulinotropic peptide; GIP agonist | 
 
  | 2084 | GIP
  (human) | Potent
  insulinotropic gut hormone; GIP agonist | 
 
  | 6699 | [D-Ala2]-GIP
  (human) | Highly
  potent GIP agonist | 
 
  | Antagonists | 5838 | [Pro3]-GIP
  (Mouse) | GIP
  receptor antagonist | 
 
  | Glucagon Receptor  Peptides | Agonists | 6927 | Glucagon
  (Human, Porcine) | Endogenous
  glucagon receptor agonist | 
 
  | Antagonists | 2216 | des-His1-[Glu9]-Glucagon
  (1-29) amide | Glucagon
  receptor antagonist | 
 
  | Other | 2094 | Oxyntomodulin
  (porcine, bovine) | Endogenous
  gut peptide; modulates feeding and metabolism | 
 
  | Glucagon-Like  Peptide 1 Receptor  Peptides | Agonists | 1933 | Exendin-4 | Potent
  GLP-1 receptor agonist | 
 
  | 5374 | GLP-1
  (7-37) | Endogenous
  bioactive GLP-1 receptor ligand | 
 
  | 1851 | Glucagon-like
  peptide 1 (1-37) (human, rat) | Endogenous
  pancreatic peptide | 
 
  | 2082 | Glucagon-like
  peptide 1 (7-36) amide (human, rat) | Potent
  insulinotropic peptide | 
 
  | 6517 | Liraglutide | Highly
  potent, long-acting GLP-1 receptor agonist | 
 
  | 2094 | Oxyntomodulin
  (porcine, bovine) | GLP-1
  receptor agonist; endogenous preproglucagon derived peptide; modulates
  feeding and metabolism | 
 
  | Antagonists | 2081 | Exendin-3
  (9-39) amide | Potent
  GLP-1 receptor antagonist | 
 
  | 3266 | GLP-1
  (9-36) amide | Metabolite
  of GLP-1-(7-36) (Cat. No. 2082) | 
 
  | Glucagon-Like  Peptide 2 Receptor  Peptides | Antagonists | 7725 | GLP-2
  (3-33) | Peptide
  antagonist of glucagon-like peptide-2 (GLP-2) receptor | 
 
  | Other | 2258 | GLP-2
  (human) | Endogenous
  hormone; displays intestinotrophic activity | 
 
  | Gonadotropin- Releasing Hormone  Receptor Peptides | Antagonists | 3536 | Cetrorelix
  Acetate | Potent
  GnRH receptor antagonist | 
 
  | GPR171 Peptides | Agonists | 6304 | BigLEN
  (mouse) | GPR171
  agonist | 
 
  | GPR83 Peptides | Agonists | 6308 | PEN
  (mouse) | GPR83
  agonist | 
 
  | Guanylyl Cyclase  Peptides | Activators | 1898 | Guanylin
  (human) | Endogenous
  activator of intestinal guanylyl cyclase | 
 
  | Heterotrimeric  G-protein GTPase  Peptides | Inhibitors | 3594 | GRK2i | GRK2
  inhibitory polypeptide; Gβ/γ antagonist | 
 
  | Other | 1193 | Melittin | Inhibits
  Gs and stimulates Gi activity | 
 
  | HIV Peptides |  | 2711 | Bay
  55-9837 | Inhibits
  HIV-1 viral replication; VPAC2 agonist | 
 
  | 2423 | DAPTA | Inhibits
  HIV-1 viral cell entry | 
 
  | Hypoxia Inducible  Factor (HIF)  Peptides | Inhibitors | 5582 | TAT-cyclo-CLLFVY | Selective
  HIF-1 dimerization inhibitor | 
 
  | Other | 7287 | FAM-DEALA-Hyp-YIPD | Fluorescent
  HIF-1α peptide | 
 
  | 7452 | FAM-DEALAHypYIPMDDDFQLRSF | Fluorescent
  HIF-1α peptide | 
 
  | Immune Checkpoint  Peptides | Inhibitors | 6515 | (D)-PPA
  1 | PD-1/PD-L1
  interaction inhibitor | 
 
  | Inflammasomes  Peptides | Inhibitors | 2163 | Z-VAD-FMK | Irreversible
  caspase inhibitor; cell-permeable | 
 
  | Influenza Virus  Peptides |  | 4611 | PBP
  10 | Displays
  antiviral activity against influenza viruses | 
 
  | Inositol Lipid  Peptides | Activators | 1983 | 740
  Y-P | Cell-permeable
  PI 3-kinase activator | 
 
  | Insulin and  Insulin-like Receptor  Peptides | Activators | 3435 | Insulin
  (human) recombinant, expressed in yeast | Endogenous
  peptide agonist | 
 
  | Integrin Peptides | Inhibitors | 6058 | ATN
  161 | α5β1
  integrin receptor antagonist | 
 
  | 3910 | BIO
  1211 | Selective
  α4β1 (VLA-4) inhibitor | 
 
  | 5870 | Cilengitide | Potent
  and selective inhibitor of integrins αvβ3 and αvβ5 | 
 
  | 3202 | Echistatin,
  α1 isoform | αVβ3 and
  glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor | 
 
  | 4725 | Eptifibatide | Glycoprotein
  IIb/IIIa inhibitor; inhibits platelet aggregation | 
 
  | 4664 | Obtustatin | Potent
  and selective α1β1 inhibitor | 
 
  | 3498 | RGDS
  peptide | Integrin
  binding sequence; inhibits integrin receptor function | 
 
  | Ligands | 7020 | LDV | α4β1 (VLA-4)
  ligand | 
 
  | Other | 4577 | LDV
  FITC | Fluorescent
  ligand for α4β1 (VLA-4) | 
 
  | Inward Rectifier  Potassium (Kir)  Channel Peptides | Blockers | 1316 | Tertiapin-Q | Selective
  blocker of inward-rectifier K+ channels | 
 
  | JNK/c-Jun Peptides | Inhibitors | 1989 | c-JUN
  peptide | Peptide
  inhibitor of JNK/c-Jun interaction | 
 
  | Kisspeptin Receptor  Peptides | Agonists | 7490 | KISS1
  305 | Kisspeptin1
  receptor agonist | 
 
  | 2570 | Kisspeptin
  10 (human) | Endogenous
  ligand for kisspeptin receptor | 
 
  | 4243 | Kisspeptin
  10 (rat) | Endogenous
  ligand for kisspeptin receptor | 
 
  | 1443 | Metastin
  (human) | Potent,
  endogenous ligand for kisspeptin receptor | 
 
  | Antagonists | 3881 | Kisspeptin
  234 | Kisspeptin
  receptor antagonist; kisspeptin 10 (Cat. No. 2570) analog | 
 
  | LDL Receptor Peptides |  | 3405 | COG
  133 | ApoE
  peptide fragmen | 
 
  | Mas-Related G Protein-Coupled Receptors  Peptides | Agonists | 1763 | BAM
  (8-22) | Potent
  MRGPRX1 agonist | 
 
  | 3374 | Cortistatin
  14 | Endogenous
  neuropeptide; binds MRGPRX2, sst1 - sst5 and ghrelin receptor | 
 
  | 3137 | Neuropeptide
  FF | MRGPRA
  agonist; also antiopioid neuropeptide; endogenous NPFF1 and
  NPFF2 agonist | 
 
  | 6551 | PAMP-12
  (human, porcine) | Potent
  MRGPRX2 agonist | 
 
  | 6552 | PAMP-20
  (human) | MRGPRX2
  agonist; also non-competitive nAChR antagonist | 
 
  | 5473 | PMX
  53 | MRGPRX2
  agonist; also potent C5a receptor antagonist | 
 
  | Antagonists | 6642 | QWF | MRGPRX2
  antagonist; also NK1 receptor antagonist | 
 
  | Matrix  Metalloprotease  Peptides | Inhibitors | 5523 | TAPI
  0 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | 6162 | TAPI
  1 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | 6013 | TAPI
  2 | ADAM-17
  (TACE) and MMP inhibitor | 
 
  | Melanin-concentrating Hormone Receptor  Peptides | Agonists | 3806 | MCH
  (human, mouse, rat) | Potent
  endogenous MCH agonist | 
 
  | Melanocortin (MC)  Receptor Peptides | Agonists | 3492 | ACTH
  (1-39) | Potent
  endogenous MC2 agonist | 
 
  | 2566 | Melanotan
  II | High
  affinity melanocortin receptor agonist | 
 
  | 3013 | [Nle4,D-Phe7]-α-MSH | Melanocortin
  receptor agonist | 
 
  | 2584 | α-MSH | Endogenous
  melanocortin receptor agonist | 
 
  | Antagonists | 1831 | HS
  014 | Selective
  MC4 receptor antagonist | 
 
  | 1832 | HS
  024 | Highly
  potent MC4 receptor antagonist | 
 
  | 5954 | MSG
  606 | Potent
  human MC1 receptor antagonist; also MC3 and MC5 partial
  agonist | 
 
  | Other | 3420 | SHU
  9119 | MC3 and
  MC4 antagonist; MC5 partial agonist | 
 
  | Microtubule Peptides |  | 6779 | Davunetide | Highly
  potent active component of ADNP; increases tau-microtubule interactions | 
 
  | Miscellaneous Compound Peptides |  | 5213 | LL
  37 | Antimicrobial
  peptide derivative of human cathelicidin | 
 
  | 3399 | Myelin
  Basic Protein (87-99) | Major
  antigenic component implicated in the pathophysiology of multiple sclerosis | 
 
  | Miscellaneous Opioid Peptides | Agonists | 1889 | [Leu5]-Enkephalin | Endogenous
  opioid agonist peptide | 
 
  | Other | 3137 | Neuropeptide
  FF | Antiopioid
  neuropeptide; also endogenous NPFF1 and NPFF2 agonist and MRGPRA
  agonist | 
 
  | Mitosis Peptides |  | 5130 | CTCE
  9908 | CXCR4
  antagonist; induces mitotic catastrophe in ovarian cancer cells | 
 
  | 1774 | Dynamin
  inhibitory peptide | Dynamin
  inhibitor | 
 
  | 1775 | Dynamin
  inhibitory peptide, myristoylated | Cell-permeable
  dynamin inhibitor | 
 
  | Motilin Receptor  Peptides | Agonists | 2264 | Motilin
  (human, porcine) | Endogenous
  peptide regulator of gastrointestinal motility | 
 
  | Myosin Light Chain  Kinase Peptides | Inhibitors | 1885 | MLCK
  inhibitor peptide 18 | Selective
  inhibitor of myosin light chain kinase | 
 
  | Natriuretic Peptide  Receptor Peptides | Agonists | 1912 | Atrial
  natriuretic factor (1-28) (rat) | Endogenous
  peptide regulating blood pressure | 
 
  | 1906 | Atrial
  natriuretic factor (1-28) (human, porcine) | Endogenous
  peptide regulating blood pressure | 
 
  | 3522 | Brain
  natriuretic peptide (1-32) (human) | Endogenous
  peptide agonist at ANP receptor A (NPR1) | 
 
  | 3520 | C-type
  natriuretic peptide (1-22) (human, rat, swine) | Endogenous
  peptide agonist at NPR2 | 
 
  | Antagonists | 6715 | A
  71915 | Highly
  potent and competitive NPRA antagonist | 
 
  | 5498 | AP
  811 | High
  affinity, selective NPR3 antagonist | 
 
  | Neural Stem Cells  Peptides |  | 4912 | GsMTx4 | Neuroprotective
  compound; enhances neurogenesis in human neural stem cells | 
 
  | 1196 | IRL-1620 | Promotes
  neural progenitor cell differentiation and maturation; ETB receptor
  agonist | 
 
  | Neuronal  Metabolism  Peptides |  | 2568 | MOG
  (35-55) | Encephalitogenic
  myelin oligodendrocyte glycoprotein fragment | 
 
  | 3399 | Myelin
  Basic Protein (87-99) | Major
  antigenic component implicated in the pathophysiology of multiple sclerosis | 
 
  | 1984 | Nogo-66
  (1-40) | Competitive
  antagonist for Nogo-66 receptor; promotes neuron regeneration | 
 
  | 2567 | PLP
  (139-151) | Encephalitogenic
  myelin proteolipid fragment | 
 
  | Neuropeptide FF/AF  Receptor Peptides | Agonists | 3137 | Neuropeptide
  FF | Endogenous
  NPFF1 and NPFF2 agonist; also MRGPRA agonist | 
 
  | 4683 | RFRP
  3 (human) | NPFF1 agonist;
  GnIH homolog | 
 
  | Neuropeptide S  Receptors Peptides | Agonists | 5857 | Neuropeptide
  S (Mouse) | Endogenous
  Neuropeptide S receptor agonist | 
 
  | Neurotensin  Receptor Peptides | Agonists | 1998 | JMV
  449 | Potent
  neurotensin receptor agonist | 
 
  | 1909 | Neurotensin | Endogenous
  neurotransmitter and endocrine modulator | 
 
  | NF-κB and IκB  Peptides | Inhibitors | 6259 | RAGE
  antagonist peptide | Receptor
  for advanced glycation end products (RAGE) antagonist | 
 
  | NFAT Peptides | Inhibitors | 3930 | NFAT
  Inhibitor | Inhibitor
  of calcineurin-mediated NFAT activation | 
 
  | 5710 | NFAT
  inhibitor, Cell Permeable | Cell
  permeable NFAT inhibitor | 
 
  | Nicotinic (α7)  Receptor Peptides | Antagonists | 2133 | α-Bungarotoxin | Selective
  α7 nAChR antagonist | 
 
  |  | 3405 | COG
  133 | α7
  nAChR antagonist; ApoE peptide fragment | 
 
  | Nicotinic Receptor  (Non-selective)  Peptides | Antagonists | 6552 | PAMP-20
  (human) | Noncompetitive
  nAChR antagonist; also MRGPRX2 agonist | 
 
  | Nicotinic Receptor  (Other Subtype)  Peptides | Antagonists | 3120 | α-Conotoxin
  AuIB | Selective
  α3β4 nAChR antagonist | 
 
  | 1340 | α-Conotoxin
  MII | Potent
  and selective α3β2 and β3 nAChR antagonist | 
 
  | 3121 | α-Conotoxin
  PIA | Selective
  antagonist of α6-containing nAChRs | 
 
  | NK1 Receptor  Peptides | Agonists | 1669 | GR
  73632 | Potent
  and selective NK1 agonist | 
 
  | 1178 | [Sar9,Met(O2)11]-Substance
  P | Potent
  and selective NK1 agonist | 
 
  | Antagonists | 6642 | QWF | NK1 receptor
  antagonist; MRGPRX2 antagonist | 
 
  | NK2 Receptor  Peptides | Agonists | 1668 | GR
  64349 | Potent,
  selective NK2 agonist | 
 
  | NK3 Receptor  Peptides | Agonists | 1068 | Senktide | Tachykinin
  NK3 agonist | 
 
  | NMDA Receptor  Peptides | Agonists | 3406 | GLYX
  13 | NMDA
  partial agonist; acts at the glycine site | 
 
  | Non-selective  AT Receptor  Peptides | Agonists | 1562 | Angiotensin
  (1-7) | Vasorelaxant
  peptide | 
 
  | 1563 | Angiotensin
  I (human, mouse, rat) | Endogenous
  precursor to angiotensin II (Cat. No. 1158) | 
 
  | 1158 | Angiotensin
  II | Potent
  vasoconstrictor peptide | 
 
  | Non-selective  CCK Peptides | Agonists | 6264 | Caerulein | CCK
  agonist | 
 
  | 1166 | CCK
  Octapeptide, sulfated | C-terminal
  octapeptide of CCK | 
 
  | Non-selective CRF  Receptor Peptides | Agonists | 1151 | CRF
  (human, rat) | Stimulates
  ACTH release | 
 
  | 1604 | Urocortin
  (human) | Endogenous
  CRF agonist | 
 
  | Antagonists | 1606 | Astressin | Potent
  CRF antagonist | 
 
  | Non-selective  Endothelin Peptides | Agonists | 1160 | Endothelin
  1 (human, porcine) | Potent
  vasoconstrictor peptide | 
 
  | 1164 | Endothelin
  2 (human) | ETA/ETB agonist | 
 
  | 1162 | Endothelin
  3 (human, rat) | Potent
  vasoconstrictor | 
 
  | Non-selective  Orexin Peptides | Agonists | 1455 | Orexin
  A (human, rat, mouse) | Endogenous
  agonist at OX1 and OX2 | 
 
  | 1456 | Orexin
  B (human) | Endogenous
  agonist at OX1 and OX2 | 
 
  | 1457 | Orexin
  B (mouse) | Endogenous
  agonist at OX1 and OX2 | 
 
  | NOP Receptor  Peptides | Agonists | 0910 | Nociceptin | Endogenous
  NOP agonist | 
 
  | Antagonists | 1552 | UFP-101 | Potent,
  selective silent antagonist for NOP | 
 
  | NPY Receptor  Peptides | Agonists | 1153 | Neuropeptide
  Y (human, rat) | Influences
  feeding and sexual behavior | 
 
  | 1173 | Neuropeptide
  Y (porcine) | Influences
  feeding and sexual behavior | 
 
  | 1176 | [Leu31,Pro34]-Neuropeptide
  Y (human, rat) | NPY
  Y1 receptor agonist | 
 
  | 1154 | Pancreatic
  Polypeptide (human) | NPY
  Y4 agonist; involved in gastrointestinal tract function | 
 
  | 1618 | Peptide
  YY (3-36) | Selective
  NPY Y2 receptor agonist | 
 
  | Nrf2 Peptides |  | 7627 | FITC-labelled
  Keap1-Nrf2 probe | Fluorescent
  Keap1-Nrf2 peptide | 
 
  | Organoid Peptides |  | 2837 | BDNF
  (human) | Improves
  the functional maturation of neurons in the neuronal organoids | 
 
  |  | 3006 | Gastrin
  I (human) | Used
  in the culture of stomach and liver organoids; CCK2 receptor agonist | 
 
  | Orphan 7-TM  Receptor Peptides | Agonists | 5151 | Prosaptide
  TX14(A) | Potent
  GPR37 and GPR37L1 agonist | 
 
  | Other Angiotensin  Receptor Peptides | Antagonists | 5937 | A
  779 | Selective
  Mas receptor (Ang-(1-7) receptor) antagonist | 
 
  | Other Apoptosis  Peptides |  | 6515 | (D)-PPA
  1 | PD-1/PD-L1
  interaction inhibitor | 
 
  |  | 3051 | TLQP
  21 | VGF-derived
  peptide | 
 
  | Other Channel  Modulator Peptides |  | 2090 | CALP1 | Inhibits
  Ca2+-sensitive ion channels; acts from cytoplasmic side | 
 
  |  | 4912 | GsMTx4 | TACAN
  blocker; also TRPC1 and TRPC6 blocker | 
 
  | Other Chemokine  Receptor Peptides | Agonists | 7116 | Chemerin-9,
  Human | Potent
  CMKLR1 agonist; c-terminal peptide of full length human chemerin | 
 
  | 7117 | Chemerin-9,
  Mouse | Potent
  CMKLR1 agonist; c-terminal peptide of full length mouse chemerin | 
 
  | Other Notch  Signaling Peptides | Inhibitors | 6477 | SAHM1 | Notch
  pathway inhibitor; prevents Notch complex assembly | 
 
  | Other Nuclear  Receptor Peptides | Degraders | 7388 | ND1-YL2 | SRC-1
  peptide-based Degrader; active in vivo | 
 
  | Other Peptide  Receptor Peptides |  | 3337 | CART
  (55-102) (rat) | Neuromodulatory
  neuropeptide fragment; satiety factor | 
 
  | Other Protease  Peptides | Inhibitors | 2511 | APC
  366 | Tryptase
  inhibitor | 
 
  | 4139 | Aprotinin | Competitive
  serine protease inhibitor | 
 
  | 3501 | Decanoyl-RVKR-CMK | Subtilisin/Kex2p-like
  proprotein convertase inhibitor | 
 
  | 1167 | Leupeptin
  hemisulfate | Inhibits
  trypsin-like/cysteine proteases | 
 
  | 6423 | Pep
  2-8 | Potent
  PCSK9 inhibitor | 
 
  | 4645 | Z-VRPR-FMK
  trifluoroacetate salt | Irreversible
  MALT1 inhibitor | 
 
  | Substrates | 3791 | Hemopressin
  (human, mouse) | Bioactive
  substrate for endopeptidase 24.15, neurolysin and ACE | 
 
  | Other RTKs Peptides | Modulators | 7712 | Semax | Hippocampal
  BDNF/trkB system modulator | 
 
  | Other Tachykinin  Peptides | Agonists | 1582 | Neurokinin
  B (human, porcine) | Endogenous
  tachykinin peptide | 
 
  | 1156 | Substance
  P | Sensory
  neuropeptide; inflammatory mediator | 
 
  | Other Wnt Signaling  Peptides |  | 5461 | Foxy
  5 | Wnt5a
  peptide mimetic | 
 
  | OX1 Receptor  Peptides | Agonists | 5115 | OXA
  (17-33) | Potent
  and selective peptide OX1 agonist | 
 
  | OX2 Receptor  Peptides | Agonists | 2142 | [Ala11,D-Leu15]-Orexin
  B | Potent
  and selective OX2 agoni | 
 
  | Oxytocin Receptor  Peptides | Agonists | 4852 | Carbetocin | Oxytocin
  analog | 
 
  | 1910 | Oxytocin | Involved
  in uterine contraction and lactation | 
 
  | Antagonists | 6332 | Atosiban | Potent
  oxytocin receptor antagonist | 
 
  | p53 Peptides |  | 7662 | Azurin
  p28 peptide | Increases
  p53 levels; binds p53 and inhibits COP1-mediated ubiquitination of p53 | 
 
  | PACAP Receptor  Peptides | Agonists | 1183 | PACAP
  1-27 | Potent
  stimulator of adenylyl cyclase | 
 
  | 1186 | PACAP
  1-38 | Potent
  stimulator of adenylyl cyclase | 
 
  | Antagonists | 3236 | PACAP
  6-38 | Potent
  PAC1 receptor antagonist | 
 
  | Parathyroid Hormone Receptor Peptides | Agonists | 6301 | Parathyroid
  hormone (1-34) (rat) | Parathyroid
  hormone (PTH) receptor agonist | 
 
  | 3011 | Parathyroid
  hormone (1-34) (human) | Parathyroid
  hormone (PTH) receptor agonist | 
 
  | PI 3-kinase Peptides | Activators | 1983 | 740
  Y-P | Cell-permeable
  PI 3-kinase activator | 
 
  | Piezo Channel  Peptides | Inhibitors | 4912 | GsMTx4 | Inhibits
  Piezo1 channels; also TRPC1 and TRPC6 blocker | 
 
  | 7170 | D-GsMTx4 | Piezo2
  and TRPC1/6 inhibitor; resistant to proteolytic digestion | 
 
  | Protease-Activated  Receptor Peptides | Agonists | 7034 | AY
  254 | Potent
  PAR2 biased agonist; exhibits bias for ERK1/2 signaling | 
 
  | 7033 | AY
  77 | Potent
  PAR2 biased agonist; exhibits bias for Ca2+ signaling | 
 
  | 1487 | AY-NH2 | Selective
  PAR4 agonist | 
 
  | 3015 | 2-Furoyl-LIGRLO-amide | Potent
  and selective PAR2 agonist | 
 
  | 3010 | SLIGKV-NH2 | PAR2 receptor
  agonist | 
 
  | 1468 | SLIGRL-NH2 | PAR2-activating
  peptide | 
 
  | 1464 | TFLLR-NH2 | PAR1-activating
  peptide | 
 
  | 7742 | TFRGAP-NH2 | PAR3
  peptide agonist | 
 
  | 1185 | Thrombin
  Receptor Agonist Peptide | Causes
  platelet aggregation and secretion | 
 
  | 3497 | TRAP-6 | PAR1 peptide
  fragment (residues 42-47); acts as a PAR1 agonist | 
 
  | Antagonists | 4751 | FSLLRY-NH2 | PAR2 peptide
  antagonist | 
 
  | 1488 | tcY-NH2 | Selective
  PAR4 antagonist | 
 
  | Inhibitors | 2511 | APC
  366 | Tryptase
  inhibitor | 
 
  | Controls | 3394 | LRGILS-NH2 | Control
  peptide for SLIGRL-NH2 (Cat. No. 1468) | 
 
  | 3393 | RLLFT-NH2 | Control
  peptide for TFLLR-NH2 (Cat. No. 1464) | 
 
  | 3392 | VKGILS-NH2 | Control
  peptide for SLIGKV-NH2 (Cat. No. 3010) | 
 
  | Protein Arginine  Methyltransferase  Peptides | Inhibitors | 5128 | C
  21 | Selective
  PRMT1 inhibitor | 
 
  | Protein Kinase A  Peptides | Inhibitors | 1904 | PKA
  inhibitor fragment (6-22) amide | Potent
  protein kinase A inhibitor | 
 
  | 6221 | PKI
  (5-24) | High
  affinity PKA inhibitor | 
 
  | 2546 | PKI
  14-22 amide, myristoylated | Cell-permeable
  protein kinase A inhibitor | 
 
  | Other | 6286 | st-Ht31 | Inhibits
  PKA/AKAP interactions; cell permeable | 
 
  | Protein Kinase C  Peptides | Antagonists | 7962 | TAT-SAMβA
  Peptide | Selective
  antagonist of Mfn1-βIIPKC association | 
 
  | Inhibitors | 1193 | Melittin | Inhibits
  protein kinase C and cAMP-dependent protein kinase | 
 
  | 2549 | ZIP | Cell-permeable
  inhibitor of atypical PKC isozyme PKMζ | 
 
  | RAGE Peptides | Antagonists | 6259 | RAGE
  antagonist peptide | RAGE
  antagonist | 
 
  | Ras GTPase Peptides | Inhibitors | 6920 | SAH-SOS1A | KRas/SOS1
  interaction inhibitor | 
 
  | Secretin Receptor  Peptides | Agonists | 1918 | Secretin
  (human) | Gastrointestinal
  peptide | 
 
  | 1919 | Secretin
  (rat) | Gastrointestinal
  peptide | 
 
  | Somatostatin (sst)  Receptor  Peptides | Agonists | 1818 | Octreotide | sst2,
  sst3 and sst5 agonist | 
 
  | 1157 | Somatostatin | Influences
  growth hormone release | 
 
  | 1165 | Somatostatin
  1-28 | sst
  agonist | 
 
  | Antagonists | 3493 | Cyclosomatostatin | Non-selective
  sst antagonist | 
 
  | 1843 | CYN
  154806 | Selective
  sst2 antagonist | 
 
  | Other | 3374 | Cortistatin
  14 | Endogenous
  neuropeptide; binds sst1 - sst5, ghrelin receptor and MRGPRX2 | 
 
  | Src Kinase Peptides | Ligands | 1935 | Caffeic
  acid-pYEEIE | Phosphopeptide
  ligand for src SH2 domain | 
 
  | Stapled Peptide  Peptides |  | 6531 | NLS-StAx-h | Wnt
  signaling inhibitor; inhibits β-catenin-transcription factor interactions | 
 
  | 6920 | SAH-SOS1A | KRas/SOS1
  interaction inhibitor | 
 
  | 6477 | SAHM1 | Notch
  pathway inhibitor; prevents Notch complex assembly | 
 
  | STAT Peptides | Activators | 3945 | Colivelin | STAT3
  activator; also protects against β-amyloid neurotoxicity | 
 
  | Stem Cell Proliferation Peptides |  | 7723 | RGD
  peptide | Directs
  association of stem cells with diverse biomaterials; increases cell spreading | 
 
  | TGF-β Receptor  Peptides | Inhibitors | 7717 | Disitertide | TGF-β1
  inhibitor | 
 
  | Toll-like Receptor  Peptides | Agonists | 4637 | Pam2CSK4 | TLR2/6
  agonist; induces TNF-α production | 
 
  | 4633 | Pam3CSK4 | TLR1/2
  agonist; induces cytokine production | 
 
  | Trk Receptor  Peptides | Agonists | 2837 | BDNF
  (human) | Activates
  TrkB and p75 receptors | 
 
  | Antagonists | 5062 | Cyclotraxin
  B | TrkB
  receptor antagonist | 
 
  | Other | 3051 | TLQP
  21 | VGF-derived
  peptide | 
 
  | TRPC Channel  Peptides | Inhibitors | 4912 | GsMTx4 | TRPC1
  and TRPC6 inhibitor; inhibits mechanosensitive ion channels | 
 
  | 7170 | D-GsMTx4 | TRPC1/6
  and Piezo2 inhibitor; resistant to proteolytic digestion | 
 
  | Two-P Potassium  Channel Peptides | Blockers | 5594 | Spadin | Potent
  K2P2.1 (TREK-1) channel blocker | 
 
  | Ubiquitin E3 Ligase  Peptides |  | 7662 | Azurin
  p28 peptide | Binds
  p53 and inhibits COP1-mediated ubiquitination of p53 | 
 
  | 7287 | FAM-DEALA-Hyp-YIPD | Fluorescent
  HIF-1α peptide; can be used to evaluate the effect of VHL binding on
  degradation activity | 
 
  | 7452 | FAM-DEALAHypYIPMDDDFQLRSF | Fluorescent
  HIF-1α peptide; can be used to evaluate the effect of VHL binding on
  degradation activity | 
 
  | 7627 | FITC-labelled
  Keap1-Nrf2 probe | Fluorescent
  Keap1-Nrf2 peptide | 
 
  | Urotensin-II  Receptor Peptides | Agonists | 1642 | Urotensin
  II (human) | Endogenous
  vasoactive agonist for the UT receptor | 
 
  | Vasopressin  Receptor Peptides | Agonists | 3396 | Desmopressin | Synthetic
  vasopressin analog; V1B and V2 agonist | 
 
  | 2935 | [Arg8]-Vasopressin | Antidiuretic
  hormone | 
 
  | Antagonists | 3377 | (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin | Selective
  vasopressin V1A antagonist | 
 
  | VIP Receptor  Peptides | Agonists | 2711 | Bay
  55-9837 | Potent
  and selective VPAC2 agonist | 
 
  | 1911 | VIP
  (human, rat, mouse, rabbit, canine, porcine) | Involved
  in neurotransmission and smooth muscle relaxation | 
 
  | Antagonists | 3054 | [D-p-Cl-Phe6,Leu17]-VIP | Selective
  VIP receptor antagonist | 
 
  | Voltage-gated  Potassium (KV)  Channel Peptides | Blockers | 5676 | Guangxitoxin
  1E | Potent
  Kv2.1 and Kv2.2 channel blocker | 
 
  | 3563 | Margatoxin | Potent
  KV1.3 channel blocker | 
 
  | 3220 | ShK-Dap22 | Extremely
  potent and selective KV1.3 blocker; suppresses T cell activation in
  vitro | 
 
  | Voltage-gated  Sodium (NaV)  Channel Peptides | Activators | 5941 | OD1 | Potent
  hNav1.4, rNav1.6 and rNav1.7 channel activator | 
 
  | Blockers | 4804 | APETx2 | NaV1.8
  and NaV1.2 blocker; also blocks ASIC3 channels | 
 
  | 4913 | Jingzhaotoxin
  III | Selective
  NaV1.5 channel blocker | 
 
  | 4914 | Phrixotoxin
  3 | Potent
  blocker of NaV1.2, NaV1.3 and NaV1.5 channels | 
 
  | 4023 | ProTx
  II | Selective
  NaV1.7 channel blocker |